New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

Westlake and Ascend close plants, Chemify opens AI-robotics lab, Formation licenses gusacitinib to Sanofi, and more ...

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

Formation Bio Licenses Gusacitinib to Sanofi: Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und . FNRD-2.627.0. Wie bewerten Sie die aktuell angezeigte Seite?

Sanofi SAN-0.18 % decrease; red down pointing triangle agreed to buy Blueprint Medicines BPMC 0.16 % increase; green up pointing triangle for up to $9.5 billion, the French drugmaker’s biggest ...

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in rare immunology diseases, in the biggest deal struck by a European ...

Sanofi shares fell 0.4 percent in Wall Street trading on Monday, while Blueprint’s soared more than 26 percent to $127.79 a share. Hudson shocked investors in 2023 when his research and ...

Sanofi has entered an agreement to acquire Vigil Neuroscience for approximately $470 million, adding a new investigational treatment for Alzheimer’s disease to the French pharmaceutical company ...

Sanofi's Focus On Alzheimer's Disease The companies expect the deal to close in the third quarter. In addition to the $470 million, Vigil shareholders will receive a contingent value right, or CVR ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.